2016 - TID Conference

This page contains exclusive content for the member of the following sections: TTS, TID. Log in to view.

Session 1: Pre-Transplant Issues

1.0 - Managing HCV Infected Kidney Transplant Candidates - When to Treat?

Presenter: Nassim, Kamar, Toulouse, France

Hepatitis C virus (HCV) infection is known to have a harmful effect after kidney transplantation. Patients’ survival is significantly reduced in HCV-positive RNA-positive kidney-transplant patients compared to those not infected by HCV. Increased risk of death in HCV-infected patients is related to sepsis, post-transplant diabetes mellitus, cardiovascular disease, and liver disease.  HCV infection was responsible for progressive liver fibrosis in a subgroup of kidney-transplant patients and cases of hepatocellular carcinoma have been reported. Grafts’ survival is also significantly reduced in HCV-positive RNA-positive kidney-transplant patients compared to those not infected by HCV. Until now, there has been no efficient and safe therapy to eliminate HCV infection after kidney transplantation. Interferon-based anti-HCV therapy is relatively contraindicated in the setting of kidney transplantation because of the increased risk of acute rejection. Hence, it was recommended to treat all HCV-positive RNA-positive candidates for kidney transplantation after transplantation. However, since new-generation direct anti-viral agents (DAAs) were shown to be highly efficient for treating HCV infection in patients with impaired kidney function (including dialysis patients) and after kidney transplantation, nowadays the choice for treating candidates for kidney transplantation before or after transplantation depends on several factors: HCV genotype, living or deceased donor, high rate of HCV-positive donors… The different strategies will be discussed.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6